

ABSTRACT OF THE DISCLOSURE

a The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect¹⁰ of binding characteristics to the kinase domain region and the

- 5 FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final
10 biological characteristics of the VEGF molecule are selectively modified.